Barbara Janota

443 total citations
16 papers, 319 citations indexed

About

Barbara Janota is a scholar working on Epidemiology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Barbara Janota has authored 16 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 9 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Barbara Janota's work include Neuroendocrine Tumor Research Advances (10 papers), Radiopharmaceutical Chemistry and Applications (8 papers) and Peptidase Inhibition and Analysis (4 papers). Barbara Janota is often cited by papers focused on Neuroendocrine Tumor Research Advances (10 papers), Radiopharmaceutical Chemistry and Applications (8 papers) and Peptidase Inhibition and Analysis (4 papers). Barbara Janota collaborates with scholars based in Poland, Austria and Switzerland. Barbara Janota's co-authors include Renata Mikołajczak, Alicja Hubalewska‐Dydejczyk, Anna Sowa‐Staszczak, Dorota Pach, Jan Kulig, Monika Tomaszuk, Agnieszka Stefańska, Aleksandra Gilis‐Januszewska, Katarzyna Fröss‐Baron and Grzegorz Kamiński and has published in prestigious journals such as PLoS ONE, Molecules and Journal of Pharmaceutical Sciences.

In The Last Decade

Barbara Janota

15 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barbara Janota Poland 8 234 196 117 115 51 16 319
Dietmar Waitz Austria 7 245 1.0× 193 1.0× 193 1.6× 198 1.7× 50 1.0× 10 466
Esther I. van Vliet Netherlands 7 379 1.6× 338 1.7× 275 2.4× 139 1.2× 22 0.4× 9 496
Katarzyna Fröss‐Baron Sweden 9 202 0.9× 164 0.8× 142 1.2× 103 0.9× 47 0.9× 14 300
Christina Swärd Sweden 10 256 1.1× 239 1.2× 158 1.4× 41 0.4× 28 0.5× 10 340
Monika Tomaszuk Poland 9 292 1.2× 241 1.2× 180 1.5× 68 0.6× 49 1.0× 17 345
Georgios S. Limouris Greece 11 119 0.5× 150 0.8× 95 0.8× 90 0.8× 27 0.5× 28 261
Agnieszka Stefańska Poland 9 326 1.4× 272 1.4× 195 1.7× 53 0.5× 60 1.2× 24 370
Swantje Engelbrecht Switzerland 3 289 1.2× 245 1.3× 216 1.8× 107 0.9× 30 0.6× 7 383
Kwadwo Antwi Switzerland 10 363 1.6× 294 1.5× 205 1.8× 43 0.4× 100 2.0× 20 427
Véronique Eltschinger Switzerland 7 258 1.1× 220 1.1× 109 0.9× 176 1.5× 36 0.7× 7 385

Countries citing papers authored by Barbara Janota

Since Specialization
Citations

This map shows the geographic impact of Barbara Janota's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Janota with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Janota more than expected).

Fields of papers citing papers by Barbara Janota

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Janota. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Janota. The network helps show where Barbara Janota may publish in the future.

Co-authorship network of co-authors of Barbara Janota

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Janota. A scholar is included among the top collaborators of Barbara Janota based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Janota. Barbara Janota is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Janota, Barbara, Alicja Hubalewska‐Dydejczyk, Melpomeni Fani, et al.. (2023). Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics. 15(3). 885–885. 2 indexed citations
2.
Maurin, Michał, et al.. (2022). [99mTc]Tc-PSMA-T4—Novel SPECT Tracer for Metastatic PCa: From Bench to Clinic. Molecules. 27(21). 7216–7216. 10 indexed citations
3.
Nock, Berthold A., Aikaterini Kaloudi, Barbara Janota, et al.. (2021). [99mTc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes. Cancers. 13(20). 5093–5093. 22 indexed citations
4.
Baldari, Giorgio, et al.. (2021). Feasibility of a Scale-down Production of [68Ga]Ga-NODAGA-Exendin-4in a Hospital Based Radiopharmacy. Current Radiopharmaceuticals. 15(1). 63–75. 7 indexed citations
5.
Ćwikła, Jarosław B., Iwona Skoneczna, Michał Maurin, et al.. (2021). Initial Experience of Clinical Use of [99mTc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study. Pharmaceuticals. 14(11). 1107–1107. 6 indexed citations
6.
Janota, Barbara, et al.. (2016). Oxidation of methionine — is it limiting the diagnostic properties of 99mTc-labeled Exendin-4, a Glucagon-Like Peptide-1 receptor agonist?. Nuclear Medicine Review. 19(2). 104–110. 10 indexed citations
7.
Sowa‐Staszczak, Anna, Małgorzata Trofimiuk–Müldner, Agnieszka Stefańska, et al.. (2016). 99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma. PLoS ONE. 11(8). e0160714–e0160714. 31 indexed citations
8.
Opydo‐Chanek, Małgorzata, et al.. (2014). Combined action of (-)-epigallocatechin-3-gallate and mafosfamide on HL-60 cells. Acta Biologica Cracoviensia. Series Zoologia. 1 indexed citations
9.
Pach, Dorota, Anna Sowa‐Staszczak, Agnieszka Stefańska, et al.. (2013). Glucagon-Like Peptide-1 Receptor Imaging with [Lys 40 (Ahx-HYNIC- 99 m Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report. International Journal of Endocrinology. 2013. 1–6. 17 indexed citations
10.
Opydo‐Chanek, Małgorzata, et al.. (2013). In vitro Response of Human Pathological Hematopoietic Cells to Cladribine. Folia Biologica. 61(3). 143–148. 2 indexed citations
11.
Janota, Barbara, et al.. (2013). Elektrostymulacja metodą Hufschmidta w leczeniu spastyczności. 39–40.
12.
Sowa‐Staszczak, Anna, Dorota Pach, Renata Mikołajczak, et al.. (2012). Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. European Journal of Nuclear Medicine and Molecular Imaging. 40(4). 524–531. 90 indexed citations
13.
Tomaszuk, Monika, Anna Sowa‐Staszczak, Dorota Pach, et al.. (2011). Dosimetry of exendin-4 based radiotracer for glucagonlike peptide-1 receptor imaging: an initial report. Journal of Physics Conference Series. 317. 12011–12011. 2 indexed citations
14.
Hubalewska‐Dydejczyk, Alicja, Anna Sowa‐Staszczak, Renata Mikołajczak, et al.. (2011). 99mTc labeled GLP-1 scintigraphy with the use of [Lys40-(Ahx-HYNIC/EDDA)NH2]-Exendin-4 in the insulinoma localization. 52. 561–561. 4 indexed citations
15.
Hubalewska‐Dydejczyk, Alicja, Katarzyna Fröss‐Baron, Renata Mikołajczak, et al.. (2006). 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. European Journal of Nuclear Medicine and Molecular Imaging. 33(10). 1123–1133. 82 indexed citations
16.
Guggenberg, Elisabeth von, Renata Mikołajczak, Barbara Janota, G Riccabona, & Clemens Decristoforo. (2004). Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis. Journal of Pharmaceutical Sciences. 93(10). 2497–2506. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dietmar Waitz Breakdown of academic impact, for papers by Esther I. van Vliet Breakdown of academic impact, for papers by Katarzyna Fröss‐Baron Breakdown of academic impact, for papers by Christina Swärd Breakdown of academic impact, for papers by Monika Tomaszuk Breakdown of academic impact, for papers by Georgios S. Limouris Breakdown of academic impact, for papers by Agnieszka Stefańska Breakdown of academic impact, for papers by Swantje Engelbrecht Breakdown of academic impact, for papers by Kwadwo Antwi Breakdown of academic impact, for papers by Véronique Eltschinger
Rankless by CCL
2026